FDA grants two national priority vouchers

The Food and Drug Administration awarded national priority vouchers under the Commissioner’s National Priority Voucher pilot program to two investigational products for their potential to increase access through affordability for American patients, the agency announced. The products are: Merck’s (MRK) Enlicitide decanoate – an oral PCSK9 inhibitor for lowering LDL cholesterol – and Merck’s Sacituzumab Tirumotecan – a trophoblast cell-surface antigen 2-directed antibody-drug conjugate.